Tyrosine News and Research

RSS

New treatment options for leukemia and myeloproliferative disorders introduced

Leukemia and myeloproliferative disorders are serious and often deadly blood cancers. Research presented today at the 51st Annual Meeting of the American Society of Hematology introduces potential new treatment options and improved diagnostic methods for patients suffering from acute promyelocytic leukemia, chronic myeloid leukemia, infant acute lymphoblastic leukemia, and myelofibrosis that are based on a better understanding of the underlying genetic causes of these conditions.

6 Dec 2009

Pre-clinical study data of Stemline Therapeutics' IL-3R targeting agents to be presented at the ASH meeting

Stemline Therapeutics, Inc. today announced that data from pre-clinical studies of its IL-3R targeting agents, SL-401 and SL-501, in both in vitro and animal models of human chronic myeloid leukemia (CML) have been selected for poster presentation at the upcoming 51st Annual Meeting of the American Society of Hematology (ASH), to be held in New Orleans from December 5-8, 2009.

4 Dec 2009

Preclinical data of Curis' HSP 90 inhibitor published

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced that preclinical data related to CUDC-305, the company’s Heat Shock Protein (HSP) 90 inhibitor, was published online this week in Molecular Cancer Therapeutics.

4 Dec 2009

ChemGenex Pharmaceuticals to present updated clinical data from its clinical trials with Omapro

ChemGenex Pharmaceuticals Limited announced today that updated clinical data from several of its clinical trials with Omapro™ (omacetaxine mepesuccinate) will be presented at the upcoming 51st American Society of Hematology Annual Meeting in New Orleans, Louisiana.

1 Dec 2009

Ambit Biosciences presents data evaluating FLT3 inhibitor in AML at the 51st ASH meeting

Ambit Biosciences Corporation announced today that there will be multiple presentations evaluating AC220, a novel second generation FLT3 inhibitor, in AML at the 51st American Society of Hematology Annual Meeting (ASH) to be held in New Orleans, LA ,December 5-8, 2009. An oral presentation will highlight results from an ongoing clinical Phase I monotherapy safety study in adults with acute myeloid leukemia (AML).

25 Nov 2009

Winship-led team identifies a way to exploit cancer cells' taste for glucose

The pedal-to-the-metal signals driving the growth of several types of cancer cells lead to a common switch governing the use of glucose, researchers at Winship Cancer Institute of Emory University have discovered.

23 Nov 2009

New biomarkers can predict patients' response to certain drugs

Recent advances in cancer therapeutics have led to the discovery of biomarkers that can predict patient response to certain drugs. Screening for mutations in the epidermal growth factor receptor (EGRF) prior to non-small cell lung cancer treatment, for example, has been shown to indentify patients who are likely to respond to treatment with erlontinib. This maximizes the drug's impact, and spares patients who are not likely to benefit from being subjected to potentially debilitating side effects.

19 Nov 2009

Cancer Cell publishes a paper on ARIAD Pharmaceuticals' Pan-BCR-ABL inhibitor

ARIAD Pharmaceuticals, Inc. today announced that the scientific journal, Cancer Cell, has published a comprehensive paper describing the design and preclinical characterization of AP24534, ARIAD’s investigational, multi-targeted kinase inhibitor.

3 Nov 2009

Positive results from Isis Pharmaceuticals' ISIS 113715 Phase 2 study in type 2 diabetes patients

Isis Pharmaceuticals, Inc. today announced positive top-line results from a Phase 2 study evaluating the safety and efficacy of ISIS 113715 in patients with type 2 diabetes. ISIS 113715 is a novel insulin sensitizer that reduces the expression of protein tyrosine phosphatase-1B (PTP-1B). The study showed consistent and statistically significant reductions in multiple short and intermediate measures of glucose control.

22 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

Genetic factors play an important role in the development of type 1 diabetes

Under the direction of Prof. Dr. Anette Ziegler, scientists of the Diabetes Research Group at Helmholtz Zentrum München and Technische Universität München investigated the formation of antibodies to a zinc transporter in children with elevated risk for type 1 diabetes. The study provided indications of an early onset of the disease when specific antibodies in the blood and specific variants of the associated zinc transporter are present in the genome.

30 Sep 2009

Pfizer to commence Phase 3 trial of oral c-Met and ALK inhibitor

Pfizer Oncology announced today that it will initiate a global, Phase 3 clinical trial of its investigational oral c-Met and ALK inhibitor, PF-02341066, versus standard of care chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) carrying the ALK (anaplastic lymphoma kinases) fusion gene, who have progressed on one prior treatment with a platinum-based chemotherapy.

26 Sep 2009

Pfizer Oncology to present early-stage research of investigational agents for cancer treatment

Pfizer Oncology will present data from across its portfolio, including results from long-term follow-up of Aromasin® (exemestane tablets) in a study of early breast cancer, updated study results from a Phase 3 study of Sutent® (sunitinib malate) in pancreatic neuroendocrine tumors (NET), and early-stage research of investigational agents PF-02341066 and figitumumab (CP-751,871) in patients with non-small cell lung cancer (NSCLC).

19 Sep 2009

Bayer HealthCare to present its clinical trial data at a joint Multidisciplinary Congress

Bayer HealthCare today announced that data from more than 30 clinical trials evaluating three products in the company's oncology portfolio - Nexavar(R) (sorafenib) tablets, regorafenib (BAY 73-4506) and Alpharadin(TM) - will be presented at the joint 15th European CanCer Organisation (ECCO) and 34th European Society for Medical Oncology (ESMO) Multidisciplinary Congress, September 20-24, 2009 in Berlin, Germany.

17 Sep 2009

HemoRANK-TKI in vitro assay service package from ReachBio

ReachBio LLC announced today the launch of HemoRANK(TM)-TKI, an in vitro assay service package that helps predict the potential of novel therapeutic tyrosine kinase inhibitors (TKIs) to cause clinical hematotoxicity (myelotoxicity or neutropenia).

16 Sep 2009

Chemgenex completes NDA submission for its omacetaxine mepesuccinate to the FDA

ChemGenex Pharmaceuticals Limited (ASX:CXS) announced today the completion of its New Drug Application (NDA) submission to the U.S. Food & Drug Administration (FDA) for OMAPRO™ (omacetaxine mepesuccinate). OMAPRO™ is being developed for the treatment of patients with chronic myeloid leukemia (CML) who have failed treatment with imatinib and who have developed the Bcr-Abl T315I mutation.

9 Sep 2009

Study to test efficacy of lapatinib in advanced hepatocellular carcinoma

Use of the molecularly targeted agent lapatinib to delay tumor growth and improve the survival of patients with inoperable hepatocellular carcinoma, or liver cancer, only benefited certain subgroups of patients. While results of this study were largely negative, patients that exhibited toxicity from the drug in the form of a skin rash appeared to have a greater tumor response and longer survival.

9 Sep 2009

GDC-0449 inhibits the Hedgehog signaling pathway

The Hedgehog signaling pathway is involved in a preliminary study and case report describing positive responses to an experimental anticancer drug in a majority of people with advanced or metastatic basal cell skin cancers. One patient with the most common type of pediatric brain cancer, medulloblastoma, also showed tumor shrinkage.

3 Sep 2009

Elsevier publishes second edition of Signal Transduction

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, announces the publication of the new second edition of Signal Transduction edited by Bastien D. Gomperts, Ijsbrand M. Kramer and Peter E.R. Tatham.

1 Sep 2009